Finance

Lists
Why is CGON down 7.65%?
Dive Deeper
CGON:NASDAQ
CG Oncology Inc
$63.46
-7.65%
(-5.25) 1D
Oct 6, 3:50:27 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CGON...
Open
$69.17
High
$69.17
Low
$63.24
Mkt. cap
5.52B
Avg. vol.
934.46K
Volume
367.74K
52-wk high
$80.97
52-wk low
$35.80
EPS
-$2.70
Shares outstanding
88.64M
No. of employees
142
Open
$69.17
High
$69.17
Low
$63.24
Mkt. cap
5.52B
Avg. vol.
934.46K
Volume
367.74K
52-wk high
$80.97
52-wk low
$35.80
EPS
-$2.70
Shares outstanding
88.64M
No. of employees
142
News stories
From web sources and news partners
About CG Oncology Inc
CEO-
Employees142
Founded2010
HeadquartersDallas, Texas, United States
SectorBiotechnology
Websitecgoncology.com
Analyst ratings
Based on 10 analysts giving stock ratings to CGON in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for CGON in the last 3 months.
Highest
Current $63.46
$108.00 (+70.20%)
Average
$92.56 (+45.87%)
Lowest
$79.00 (+24.50%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gregory Renza
Truist Financial
Buy
Maintained
-
-
09/10/2026
David Dai
UBS
Buy
Reiterated
$90.00
+41.8%
08/21/2026
Sean Laaman
Morgan Stanley
Buy
Reiterated
$93.00
+46.6%
08/17/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$108.00
+70.2%
08/07/2026
Joshua Schimmer
Cantor Fitzgerald
Buy
Reiterated
$105.00
+65.5%
08/06/2026
Kelsey Goodwin
Piper Sandler
Buy
Reiterated
$85.00
+34%
08/07/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$79.00
+24.5%
08/06/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$88.00
+38.7%
08/07/2026
Boris Peaker
JonesTrading
Buy
Maintained
$85.00
+34%
08/06/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$100.00
+57.6%
08/07/2026
Kalpit Patel
Wolfe Research
Hold
Maintained
-
-
05/26/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$80.00
+26.1%
05/18/2026
Brian Cheng
J.P. Morgan
Buy
Reiterated
$96.00
+51.3%
05/11/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/11/2026
Soumit Roy
JonesTrading
Buy
Maintained
$85.00
+34%
04/06/2026
Bradley Canino
Guggenheim
Buy
Reiterated
$90.00
+41.8%
02/27/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.90 / -$0.64
-40.06%miss
Revenue / Est. (USD)
1.16M / 362.64K
+219.05%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.67M
2.32M
1.08M
1.16M
Cost of goods sold
29.46M
33.03M
46.69M
58.58M
Cost of revenue
29.46M
33.03M
46.69M
58.58M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
23.33M
17.99M
20.78M
28.98M
Operating expense
23.33M
17.99M
20.78M
28.98M
Total operating expenses
52.80M
51.02M
67.47M
87.56M
Operating income
-51.13M
-48.70M
-66.39M
-86.40M
Other non operating income
-100.00K
-53.00K
-101.00K
16.00K
EBT including unusual items
-43.81M
-41.31M
-60.20M
-79.06M
EBT excluding unusual items
-43.81M
-41.31M
-60.20M
-79.06M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-43.81M
-41.31M
-60.20M
-79.06M
Net profit margin
-2,629.53%
-1,779.03%
-5,558.82%
-6,832.84%
Earnings per share
-0.57
-0.51
-0.71
-0.90
Interest and investment income
7.42M
7.44M
6.29M
7.33M
Interest expense
-
-
-
-
Net interest expenses
7.42M
7.44M
6.29M
7.33M
Depreciation and amortization charges
-
-
-
-
EBITDA
-50.71M
-47.85M
-65.55M
-85.55M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps